Conavi files amended final prospectus

Ms. Christina Cameron reports CONAVI MEDICAL CORP. ANNOUNCES FILING OF AMENDED & RESTATED FINAL PROSPECTUS Conavi Medical Corp. has provided an update in respect of its previously announced public offering of common shares of the company and/or prefinanced common share purchase warrants of the company in lieu of common shares. The offering is being conducted on a commercially reasonable effort agency basis for the issuance of a minimum of 26,666,667 securities and a maximum of 33,333,333 securities at a price of 45 cents per common share or 44.999 cents per prefinanced warrant, for gross proceeds of between $12-million and $15-million. Each prefinanced warrant issued in lieu of a common share at the election of any purchaser entitles the holder thereof to acquire one common share at an exercise price of 0.001 cent per common share. The prefinanced warrants will not expire and may be exercised on a net or cashless basis. The company intends to use the net proceeds from the offering to obtain U.S. Food and Drug Administration 510(k) clearance of the next-generation Novasight hybrid system, as well as complete a targeted market release in the United States. The company also intends to use the net proceeds for working capital and other general corporate purposes. The offering is expected to be completed pursuant to the terms and conditions of an amended and restated agency agreement entered into between the company and Bloom Burton Securities Inc. The company filed an amended and restated final short form prospectus on Jan. 7, 2026, with the securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario, which amends and restates the final short form prospectus filed on Dec. 18, 2025. There will not be any sale of the securities until a receipt for the A&R final prospectus has been issued. The offering may be completed in one or more tranches, and is expected to close initially on or about Jan. 13, 2026, or such other date as may be mutually agreed to by the company and the agent. The offering is subject to the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange. The company will pay to the agent a cash fee equal to 6.5 per cent of the gross proceeds raised under the offering, and grant the agent compensation options equal to 6.5 per cent of the aggregate number of securities issued under the offering, provided, however, the agent will receive a reduced cash commission of 3.25 per cent and no compensation options in respect of securities sold to certain purchasers on a president's list to be agreed to between the company and the agent. Each compensation option shall entitle the holder to buy one common share at the same price per common share as under the offering. The compensation options shall be exercisable until that date which is 24 months following the closing date. In addition, the securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws. Access to the A&R final prospectus and any amendments to such documents will be provided in accordance with securities legislation relating to procedures for providing access to a short form prospectus and any amendment thereto. The A&R final prospectus (when filed) will be accessible on SEDAR+. Alternatively, an electronic or paper copy of the A&R final prospectus (when filed), as well as any amendment to such documents, may be obtained without charge from the agent by e-mail at [email protected], by telephone at 416-640-7585, or by providing the contact with an e-mail address or address, as applicable. The A&R final prospectus (when filed) contains important, detailed information about the company and the offering. Prospective investors should read the A&R final prospectus (when filed) before making an investment decision. About Conavi Medical Corp. Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight hybrid system is the first to combine intravascular ultrasound and optical coherence tomography into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight hybrid system has 510(k) regulatory clearance in the United States, Canada, China and Japan. We seek Safe Harbor.